Merck licenses oncology research programmes from Vertex Pharmaceuticals

Merck has signed a licensing agreement with Vertex Pharmaceuticals pertaining to the worldwide development and commercialisation of four new cancer programmes.

In a move that will help Merck to become a leader in this field, the company will license two clinical-stage programmes targeting DNA damage and repair, along with two additional novel preclinical programmes.

The clinical-stage assets include an ataxia telangiectasia and Rad3-related programme comprised of two compounds, VX-970 and VX-803, which are being investigated across a variety of tumours and patient subtypes, as well as a DNA-dependent protein kinase inhibitor programme including the clinical candidate VX-984, which is being assessed as a means of treating advanced solid tumours.

Meanwhile, the preclinical programmes include one immuno-oncology therapy aimed against an attractive target with first-in-class potential, and a second that focuses on a completely novel target.

Under the terms of the deal, Vertex will receive an upfront payment of $230 million (186.61 million pounds), in addition to royalties on future net sales. Merck will assume full responsibility for the development and commercialisation of all four programmes.

Belen Garijo, chief executive officer for healthcare and member of the executive board of Merck, said: "This deal underscores our commitment to accelerate innovation for cancer patients, and we are excited for the opportunity to build on Vertex's rigorous science and advance these leading programmes."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.